Advanced Search

Oncology & Hematology Coding Alert

You Be the Coder:

Get the 411 on the FDA’s Latest REGEN-COV Authorization

Published on Tue Aug 24, 2021

Question: The Food and Drug Administration (FDA) recently approved REGEN-COV for emergency use as a postexposure prophylaxis for immunocompromised patients exposed to COVID-19. What should we know about the treatment, and how should we go about coding it? North Carolina Subscriber Answer: On July 30, 2021, the FDA expanded the emergency use of REGEN-COV (casirivimab and imdevimab, administered together) from [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All